Contact SCGE




Gene Therapy Trial Report

Summary

Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease


NCTID NCT04819841 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Sickle Cell Disease
Disease Ontology Term DOID:0081445
Compound Name KMAU-001
Compound Alias nulabeglogene autogedtemcel
Sponsor Kamau Therapeutics
Funder Type Industry
Recruitment Status
Enrollment Count 15 (ESTIMATED)
Results Posted Not Available

Therapy Information


Target Gene/Variant HBB
Therapy Type Gene editing
Therapy Route Ex-vivo
Mechanism of Action Mutation correction
Route of Administration Intravenous
Drug Product Type Autologous cells
Target Tissue/Cell CD34+ cells
Delivery System Viral transduction
Vector Type AAV6
Editor Type Cas9 mRNA
Dose 1 Transduced CD34+ cells

Study Record Dates


Current Stage Phase1, Phase2
Submit Date 2021-03-24
Completion Date 2028-12-31
Last Update 🔄 2026-03-11

Participation Criteria


Eligible Age 12 Years - 40 Years
Standard Ages Child, Adult
Sexes Eligible for Study ALL
Eligibility Criteria
Inclusion Criteria: * ≥12 to ≤ 40 years * Severe disease, as defined by having experienced at least one of the following SCD-related events despite appropriate supportive care measures: * recurrent severe VOC (≥ 4 episodes in the preceding 2 years) * ACS (≥ 2 episodes in the prior 2 years with at least one episode in the past year) * Lansky/Karnofsky performance status of ≥ 80 Exclusion Criteria: * Available 10/10 HLA-matched sibling donor * Prior HSCT or gene therapy * Prior or current malignancy or myeloproliferative or a significant coagulation or immunodeficiency disorder * Clinically significant and active bacterial, viral, fungal or parasitic infection * Pregnancy or breastfeeding in a postpartum female * Presence of a chromosomal abnormality/mutation that may put the participant at an increased risk for MDS or AML per investigator's judgment
View Inclusion and Exclusion Criteria at ClinicalTrials.gov

Locations


No.of Trial Sites 4
Locations United States

Regulatory Information


Has US IND True
FDA Designations
Recent Updates Product was previously developed by Graphite Bio

Resources/Links